Mei Ri Jing Ji Xin Wen·2025-09-14 12:19Group 1 - Zhaoli Pharmaceutical (SZ 300181) announced an investor research meeting scheduled for September 12, 2025, where the company’s board secretary, Wu Ying, will participate and address investor inquiries [1] - For the first half of 2025, Zhaoli Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 78.39%, pharmaceutical distribution for 21.35%, and other businesses for 0.26% [1] - As of the report, Zhaoli Pharmaceutical has a market capitalization of 12.9 billion yuan [1] Group 2 - A significant breakthrough has been reported regarding a new drug from China, recognized for its breakthrough efficacy by both Chinese and American authorities, generating excitement at the World Lung Cancer Conference [1]